TeleRanked

Run a telehealth clinic? Claim your profile on TeleRanked.

Regulatory

DEA Proposes 2027 Controlled-Substance Production Quotas, Keeping Higher ADHD Stimulant Limits and Cutting Opioids

On November 10, 2026, the DEA proposed the 2027 aggregate production quotas that cap how much of each Schedule I and II controlled substance may be made in the United States. The proposal carries forward higher manufacturing limits for the ADHD stimulants amphetamine, lisdexamfetamine and methylphenidate, citing FDA shortage concerns the FDA tied in part to the growth of telemedicine, while proposing to cut Schedule II opioid quotas. Public comments are due December 10, 2026, and the quotas are proposed, not final.

The TeleRanked Editors·Updated November 11, 2026·9 min read

Quick answer

On November 10, 2026, the DEA published a proposed notice (Docket DEA-1730P) setting the 2027 aggregate production quotas that cap how much of each Schedule I and II controlled substance may legally be manufactured in the United States, with public comments due December 10, 2026. The agency proposes to carry forward higher manufacturing limits for the Schedule II stimulants used to treat ADHD (amphetamine, lisdexamfetamine and methylphenidate), citing FDA concerns about shortages that the FDA linked in part to the growth of telemedicine, while proposing to reduce quotas for Schedule II opioids as the FDA projects a 9.68 percent average decline in their medical use. The 2027 quotas are proposed, not final.

Key takeaways

  • →The 2027 quotas are a proposal open for public comment through December 10, 2026 (Docket DEA-1730P). A final order follows after the DEA reviews comments and holds a hearing if the Administrator decides to, so nothing here is settled yet.
  • →For ADHD stimulants, the DEA proposes to hold 2027 limits at the higher levels it set for lisdexamfetamine and methylphenidate and to raise amphetamine further. The FDA projected a 3.93 percent average rise in Schedule II stimulant medical use for 2027 and flagged shortages it linked partly to the growth of telemedicine.
  • →On the same day, the DEA issued a separate final order (effective November 10, 2026, Docket DEA-1568M) that raised the 2026 quotas for d,l-amphetamine, d-amphetamine, methylphenidate and hydromorphone after manufacturers reported them in shortage on the FDA list and requested more under the expedited shortage authority in 21 U.S.C. 826(h).
  • →The DEA proposes to reduce 2027 quotas for Schedule II opioids including fentanyl, hydrocodone, hydromorphone, oxycodone and oxymorphone, reflecting an FDA projection that opioid medical use will fall 9.68 percent on average.
  • →A quota sets a ceiling on how much may be made, not a floor, so a higher limit does not by itself guarantee that a specific ADHD medication reaches pharmacy shelves.

The DEA has proposed how much of each controlled substance drugmakers may produce next year, and the plan would keep the higher manufacturing limits the agency recently set for ADHD stimulants while trimming limits for prescription opioids. In a notice published in the Federal Register on November 10, 2026 (Docket DEA-1730P), the agency laid out the proposed 2027 aggregate production quotas for Schedule I and II controlled substances and opened a public comment period that closes December 10, 2026. The stimulant piece matters for virtual care: the FDA told the DEA it was concerned about ADHD medication shortages that it tied in part to the growth of telemedicine, and the DEA said it is proposing higher stimulant limits in part to address those concerns.

What the DEA proposed

An aggregate production quota is the total amount of a given controlled substance that the DEA will allow all manufacturers combined to produce in a calendar year. The agency sets these limits under the Controlled Substances Act using criteria in 21 CFR part 1303, weighing disposal and inventory trends, projected demand, the extent of diversion, and estimates of legitimate domestic medical need that the FDA provides each year. In July 2026, the FDA gave the DEA its usage predictions for 2027, which the agency says it used to build the proposal.

The November 10 notice is a proposal, labeled a notice with request for comments, not a final rule. Interested parties may file written comments referencing Docket DEA-1730P on or before December 10, 2026. The Administrator may hold a public hearing on issues the comments raise, and only after that process will the DEA publish a final order establishing the 2027 quotas.

Higher limits for ADHD stimulants

The FDA predicted that domestic medical use of Schedule II stimulants, including d-amphetamine, d,l-amphetamine, lisdexamfetamine and methylphenidate, will rise 3.93 percent on average in 2027 from 2026 levels. These are the medicines prescribed for ADHD, and their supply has been a running problem for virtual clinics that treat the condition. The FDA also raised concerns about drug shortages it linked to the growth of telemedicine, along with supply-chain, manufacturing and business factors, which the DEA says it weighed.

The DEA says it recently proposed to increase the 2026 quotas for both lisdexamfetamine and methylphenidate and is proposing the same higher values for 2027. For d,l-amphetamine and d-amphetamine, it is proposing 2027 limits above the 2026 revised levels, citing growth in prescribing, export and global demand and the need to keep enough inventory for makers of FDA-approved products. The agency reviewed domestic usage data from IQVIA and export data from its own systems, and that analysis projected use of d-amphetamine and d,l-amphetamine each rising 6.98 percent.

A separate order already raised 2026 stimulant supply

On the same day, the DEA published a separate final order (Docket DEA-1568M) that took effect November 10, 2026, adjusting the 2026 quotas upward for d,l-amphetamine, d-amphetamine, methylphenidate and hydromorphone. That order used the expedited shortage authority in 21 U.S.C. 826(h), which directs the DEA to review quotas when a drug appears on the FDA shortage list and to raise them if it finds an increase is needed to address the shortage.

The DEA said manufacturers had reported shortages of amphetamine mixed-salts tablets, methylphenidate tablets and film, and hydromorphone injectables on the FDA list, and had asked for larger individual quotas. The FDA predicted that 2026 domestic medical need would rise 23.6 percent for d,l-amphetamine, 23.7 percent for d-amphetamine, 23.4 percent for methylphenidate and 20.9 percent for hydromorphone compared with 2025. The agency concluded that higher 2026 limits were warranted to meet demand and rebuild reserve stocks.

Opioid quotas proposed to fall

The direction is reversed for prescription opioids. The FDA predicted that medical use of Schedule II opioids will decline 9.68 percent on average in 2027, across fentanyl, hydrocodone, hydromorphone, oxycodone and oxymorphone. The DEA is proposing 2027 reductions for each of those substances from the 2026 revised levels, after factoring in the potential for diversion as the statute requires. Hydromorphone sits in both columns: the DEA raised its 2026 limit mid-year to cover an injectable shortage, and is now proposing a lower 2027 figure in line with the FDA's projection of declining use.

Research substances and other changes

The proposal raises research quotas for two Schedule I substances, MDMA and ibogaine, to support manufacturing tied to a growing number of trials studying them for conditions including PTSD and depression. The DEA connected that increase to two executive orders, one prioritizing addiction treatment and recovery and one directing a pathway for eligible patients to access certain psychedelic drugs under the Right to Try Act. The notice also proposes a first-ever quota for O-desmethyltramadol, which the DEA temporarily placed in Schedule I in August 2026, a higher pentobarbital quota to help stock a strategic reserve of active pharmaceutical ingredients, and lower quotas for acetyl fentanyl, heroin and fentanyl-related substances based on reduced manufacturer need.

How the DEA weighs diversion

For five covered controlled substances, the law requires the DEA to estimate how much is diverted and to subtract that from the quota it would otherwise set. To do so, the agency pulled prescription drug monitoring program data from states and looked at red-flag metrics it treats as signs of possible diversion, including patients who saw three or more prescribers in a 90-day period and were dispensed an opioid after each visit, a pattern it associates with doctor shopping, and prescriptions exceeding 240 morphine milligram equivalents per day. The analysis shapes the opioid numbers more than the stimulant numbers, but it is part of the same calculation telehealth prescribers operate within when they write for controlled substances.

What this means for telehealth

Production quotas do not decide who may prescribe a controlled substance by video or how, which is governed by separate DEA telemedicine prescribing rules. What they do decide is how much raw supply exists. For virtual ADHD care, the proposal signals that the DEA intends to keep stimulant manufacturing ceilings at the higher levels it has moved to this year, which is the supply side of a shortage that has forced patients and online clinics to chase medication between pharmacies. For telehealth pain and palliative care, the proposed opioid cuts point the other way, toward a tighter national supply in 2027. Because these are ceilings rather than guaranteed output, the effect on any single product still depends on manufacturers choosing to produce up to the limit.

What patients and clinicians can watch

This is general information, not medical or legal advice. A few things worth tracking while the proposal moves through comment:

  • The quotas are not final. The DEA will publish a final order for 2027 after the December 10, 2026 comment period, and the numbers can change.
  • A higher stimulant quota is a supply ceiling, not a promise that a specific ADHD medication will be in stock at a given pharmacy on a given day.
  • Patients and organizations can file comments on Docket DEA-1730P through the federal rulemaking portal before the deadline.
  • For questions about your own prescription or a shortage affecting it, talk to your prescribing clinician and pharmacist rather than relying on the quota figures alone.

Frequently asked questions

What did the DEA propose on November 10, 2026?+

The DEA proposed the 2027 aggregate production quotas, the ceilings on how much of each Schedule I and II controlled substance may be manufactured in the United States next year. The proposal keeps higher limits for ADHD stimulants and reduces limits for Schedule II opioids. It is a proposal open for comment, not a final rule.

Are the 2027 quotas final?+

No. The notice is a proposal with a comment period that closes December 10, 2026. The DEA may hold a hearing and will issue a final order afterward, so the figures can still change.

Will this fix the ADHD stimulant shortage?+

It is a supply-side step, not a guaranteed fix. A quota sets a maximum amount that may be produced, so raising it removes one constraint, but manufacturers still have to make and distribute the product, and shortages have also been tied to manufacturing, supply-chain and business factors. The DEA separately raised the 2026 amphetamine and methylphenidate quotas mid-year after those drugs appeared on the FDA shortage list.

Why is the DEA proposing to cut opioid quotas?+

The FDA predicted that medical use of Schedule II opioids will fall 9.68 percent on average in 2027, and the law requires the DEA to account for diversion when it sets quotas. Based on those inputs the agency is proposing lower 2027 limits for fentanyl, hydrocodone, hydromorphone, oxycodone and oxymorphone.

Does this change who can prescribe stimulants through telehealth?+

No. Aggregate production quotas cap manufacturing, not prescribing. The rules for prescribing controlled substances by telemedicine are set separately by the DEA and are not changed by this notice.

How can the public comment, and by when?+

Written and electronic comments referencing Docket DEA-1730P must be submitted or postmarked on or before December 10, 2026. The electronic federal docket system stops accepting comments at 11:59 p.m. Eastern Time on the last day.

Sources

  1. 1.Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027 (Docket DEA-1730P) · Federal Register (Drug Enforcement Administration)
  2. 2.Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h) (Docket DEA-1568M) · Federal Register (Drug Enforcement Administration)
  3. 3.Federal Register Volume 91, Number 216 (full text via the Government Publishing Office), DEA 2027 proposed quotas · U.S. Government Publishing Office (govinfo.gov)

Related